Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia

Vaccine

Volumn 27, Issue 34, 2009, Pages 4551-4559

  Pathirana, D ^b   Hillemanns, P ^a,c   Petry, K U ^a,d   Becker, N ^e   Brockmeyer, N H ^f   Erdmann, R ^b   Gissmann, L ^a,e   Grundhewer, H ^g   Ikenberg, H ^a,h   Kaufmann, A M ^a,b   Klussmann J ⁱ   Kopp, I ^j   Pfister, H ^a,i   Rzany, B ^b   Schneede, P ^a,k   Schneider, A ^a,b   Smola, S ^a,i   Winter Koch, N ^l   Wutzler, P ^m   Gross, G ^a,n  

^a HPV Management Forum working group of the Paul Ehrlich Gesellschaft für Chemotherapie e V   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Klinikum Wolfsburg   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g Niedergelassener Arzt für Kinder und Jugendheilkunde   (Germany)

^h MVZ für Zytologie und Molekularbiologie Frankfurt GbR CytoMol   (Germany)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k Klinikum Memmingen   (Germany)

^l Vulva CA Forum   (Germany)

^m JENA UNIVERSITY HOSPITAL   (Germany)

ⁿ UNIVERSITY OF ROSTOCK   (Germany)

more..

Author keywords

CIN; Genital warts; HPV vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ANUS CARCINOMA; ARTHRALGIA; BREAST FEEDING; BRONCHOSPASM; CANCER PREVENTION; CANCER SCREENING; CHILL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GERMANY; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MYALGIA; NAUSEA; PAIN; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; REVIEW; SKIN REDNESS; SWELLING; UNSPECIFIED SIDE EFFECT; URTICARIA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VAGINA BLEEDING; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA TUMOR; WART VIRUS;

EID: 67649774217     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.086     Document Type: Review

References (10)

1. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 Nov (21) (2002) 1645-1651
2. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 Jan (1) (2006) 18-27
3. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 Nov (9447) (2004) 1757-1765
4. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 Apr (9518) (2006) 1247-1255
5. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 June (9580) (2007) 2161-2170
6. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 May (19) (2007) 1928-1943
7. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 May (19) (2007) 1915-1927
8. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 May (5) (2005) 271-278
9. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 Dec (11) (2006) 1459-1466
10. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 May (9574) (2007) 1693-1702